The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Clinical trial NCT04136366 · COMPLETED

Trial details

NCT number: NCT04136366
Sponsor: Aldeyra Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Proliferative Vitreoretinopathy

Start date: 2019-11-15
Primary completion: 2022-06-14
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.